A Phase 3 interventional study of E/C/F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 21 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-23.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) plus a third antiretroviral (ARV) agent in participants harboring the archived nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance mutation M184V and/or M184I in human immunodeficiency virus (HIV) -1 reverse transcriptase.
This is a two part study. If the rate of virologic failure in Part 1 is deemed acceptable, once the internal data monitoring committee officially completes the interim review, the study will continue to Part 2.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Proviral deoxyribonucleic acid (DNA) test must not have additional exclusion resistance mutations against PIs, NRTIs and INSTIs
A female individual is eligible to enter the study if it is confirmed that she is:
Male individuals must agree to use the protocol-specified method(s) of contraception during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from screening throughout the study period and for 30 days following the last study drug dose
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks. Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG).
Drug: E/C/F/TAF
Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks. Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG.
Drug: E/C/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
150/150/200/10 mg FDC tablets administered orally once daily
Also known as: Genvoya®
Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR)
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 12 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.
Time frame: Week 12
Percentage of Participants With Emergence of New Mutations in HIV-1 Reverse Transcriptase and Integrase
Development of new resistance mutations was assessed in participants who developed virologic failure, defined as 2 consecutive HIV-1 RNA result ≥ 50 copies/mL at any point in the study or with HIV-1 RNA ≥ 50 copies/mL at last visit.
Time frame: Day 1 up to 48 weeks
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using PVR
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 24 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using PVR
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).
Time frame: Week 12
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 12 Using the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).
Time frame: Week 12
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 24 Using the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Using the FDA Snapshot Analysis
The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Failure (M = F) Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = F Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = F Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
Time frame: Week 48
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Excluded (M = E) Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = E Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
Time frame: Week 48
Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 12
Time frame: Baseline (Day 1); Week 12
Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline (Day 1); Week 24
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline (Day 1); Week 48
Change From Baseline in CD4 Percentage (%) at Week 12
Time frame: Baseline (Day 1); Week 12
Change From Baseline in CD4 % at Week 24
Time frame: Baseline (Day 1); Week 24
Change From Baseline in CD4 % at Week 48
Time frame: Baseline (Day 1); Week 48
Participants were enrolled at study sites in the United States and Europe. The first participant was screened on 17 December 2015. The last study visit occurred on 11 July 2019.
| Milestone | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF |
|---|---|---|
| Started | 38 | 28 |
| Completed | 34 | 26 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrew consent | 1 | 0 |
| Withdrew: Enrolled and never treated | 1 | 1 |
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 12 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 12 as Defined by Pure Virologic Response (PVR) | 100.0 (90.3 to 100.0) | 100.0 (86.8 to 100.0) | 100.0 (94.2 to 100.0) |
Development of new resistance mutations was assessed in participants who developed virologic failure, defined as 2 consecutive HIV-1 RNA result ≥ 50 copies/mL at any point in the study or with HIV-1 RNA ≥ 50 copies/mL at last visit.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With Emergence of New Mutations in HIV-1 Reverse Transcriptase and Integrase | 0 | 0 | 0 |
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 24 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using PVR | 100.0 (90.3 to 100.0) | 100.0 (86.8 to 100.0) | 100.0 (94.2 to 100.0) |
The percentage of participants with PVR for HIV-1 RNA cutoff at 50 copies/mL at Week 48 was summarized. PVR was the percentage of participants who did not have a confirmed virologic rebound. Virologic rebound was defined as 2 consecutive HIV-1 RNA values ≥ 50 copies/mL or the last available HIV-1 RNA value ≥ 50 copies/mL during the study followed by premature discontinuation from the study.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using PVR | 100.0 (90.3 to 100.0) | 100.0 (86.8 to 100.0) | 100.0 (94.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the FDA Snapshot Analysis | 91.7 (77.5 to 98.2) | 96.2 (80.4 to 99.9) | 93.5 (84.3 to 98.2) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the FDA Snapshot Analysis | 91.7 (77.5 to 98.2) | 100.0 (86.8 to 100.0) | 95.2 (86.5 to 99.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the FDA Snapshot Analysis | 88.9 (73.9 to 96.9) | 96.2 (80.4 to 99.9) | 91.9 (82.2 to 97.3) |
The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 12 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 71 and 98 (inclusive).
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 12 Using the FDA Snapshot Analysis | 91.7 (77.5 to 98.2) | 96.2 (80.4 to 99.9) | 93.5 (84.3 to 98.2) |
The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 24 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 24 window was between Day 141 and 210 (inclusive).
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 24 Using the FDA Snapshot Analysis | 88.9 (73.9 to 96.9) | 100.0 (86.8 to 100.0) | 93.5 (84.3 to 98.2) |
The percentage of participants with HIV-1 RNA \< 20 copies/mL at Week 48 was also analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 12 window was between Day 295 and 378 (inclusive).
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48 Using the FDA Snapshot Analysis | 88.9 (73.9 to 96.9) | 96.2 (80.4 to 99.9) | 91.9 (82.2 to 97.3) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Failure (M = F) Approach | 97.2 (85.5 to 99.9) | 96.2 (80.4 to 99.9) | 96.8 (88.8 to 99.6) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = F Approach | 91.7 (77.5 to 98.2) | 100.0 (86.8 to 100.0) | 95.2 (86.5 to 99.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the M = F approach. In this approach, all missing data was treated as HIV-1 RNA ≥ 50 copies/mL.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = F Approach | 91.7 (77.5 to 98.2) | 96.2 (80.4 to 99.9) | 93.5 (84.3 to 98.2) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 12 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 12 Using the Missing = Excluded (M = E) Approach | 100.0 (90.0 to 100.0) | 96.2 (80.4 to 99.9) | 98.4 (91.2 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 Using the M = E Approach | 100.0 (89.4 to 100.0) | 100.0 (86.8 to 100.0) | 100.0 (93.9 to 100.0) |
The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was also analyzed using the M = E approach. In this approach, all missing data was excluded in the computation of the proportions.
| percentage of participants | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 Using the M = E Approach | 100.0 (89.4 to 100.0) | 100.0 (86.3 to 100.0) | 100.0 (93.8 to 100.0) |
| cells/µL | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 12 | -47 ± 194.1 | -6 ± 116.1 | -30 ± 165.1 |
| cells/µL | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24 | -40 ± 162.1 | 28 ± 212.5 | -10 ± 187.4 |
| cells/µL | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | -6 ± 131.9 | 27 ± 120.4 | 9 ± 126.8 |
| percentage of CD4 cells | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in CD4 Percentage (%) at Week 12 | -0.4 ± 3.37 | 1.5 ± 3.01 | 0.4 ± 3.33 |
| percentage of CD4 cells | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in CD4 % at Week 24 | 0.1 ± 3.25 | 1.1 ± 4.30 | 0.5 ± 3.75 |
| percentage of CD4 cells | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total E/C/F/TAF |
|---|---|---|---|
| Change From Baseline in CD4 % at Week 48 | 0.2 ± 3.12 | 1.5 ± 3.64 | 0.8 ± 3.39 |
Collected over First dose date up to the last dose date (maximum: 48 Weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total E/C/F/TAF | 1/64 (1.6%) | 5/64 (7.8%) | 26/64 (40.6%) |
| Event | Total E/C/F/TAF |
|---|---|
| DeathGeneral disorders | 1/64 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/64 |
| Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/64 |
| Tonsil cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/64 |
| Acute kidney injuryRenal and urinary disorders | 1/64 |
| ProteinuriaRenal and urinary disorders | 1/64 |
| Renal failureRenal and urinary disorders | 1/64 |
| Event | Total E/C/F/TAF |
|---|---|
| AstheniaGeneral disorders | 7/64 |
| BronchitisInfections and infestations | 7/64 |
| NasopharyngitisInfections and infestations | 7/64 |
| HeadacheNervous system disorders | 6/64 |
| DiarrhoeaGastrointestinal disorders | 5/64 |
| Back painMusculoskeletal and connective tissue disorders | 5/64 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/64 |
| DizzinessNervous system disorders | 4/64 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| Mean | 50 ± 9.2 | 52 ± 9.5 | 51 ± 9.3 |
| Sex: Female, Male(Participants) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| Female | 8 | 9 | 17 |
| Male | 29 | 18 | 47 |
| Race/Ethnicity, Customized(Participants) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| Ethnicity — Hispanic or Latino | 6 | 4 | 10 |
| Ethnicity — Not Hispanic or Latino | 27 | 21 | 48 |
| Ethnicity — Not Permitted | 4 | 2 | 6 |
| Race/Ethnicity, Customized(Participants) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 0 | 0 | 0 |
| Race — Black | 7 | 8 | 15 |
| Race — Native Hawaiian or Pacific Islander | 0 | 0 | 0 |
| Race — White | 27 | 17 | 44 |
| Race — Not Permitted | 3 | 2 | 5 |
| Region of Enrollment(Participants) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| United States | 3 | 5 | 8 |
| Italy | 2 | 3 | 5 |
| France | 14 | 15 | 29 |
| Germany | 4 | 1 | 5 |
| Spain | 14 | 3 | 17 |
| HIV-1 RNA(log10 copies/mL) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| Mean | 1.29 ± 0.056 | 1.29 ± 0.046 | 1.29 ± 0.052 |
| HIV-1 RNA Categories(Participants) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| < 50 copies/mL | 37 | 27 | 64 |
| ≥ 50 copies/mL | 0 | 0 | 0 |
| Cluster Determinant 4+ (CD4+) Cell Count(cells/µL) | Part 1: E/C/F/TAF | Part 2: E/C/F/TAF | Total |
|---|---|---|---|
| Mean | 740 ± 319.6 | 665 ± 312.7 | 708 ± 316.4 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Dec 2015 to primary completion in Oct 2018, 33 months.
Results were first posted in Nov 2019, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide